An LP's diversification strategy across different venture funds is undermined when every fund converges on a single theme like AI. This creates a highly correlated portfolio, concentrating systemic risk rather than spreading it. The traditional diversification benefits of investing across multiple managers, stages, and geographies are nullified.

Tech-focused venture firms are finding their AI investment thesis fails in biotech. Despite massive paper profits in tech AI, their biotech AI portfolios show negative returns. This is because AI has yet to solve the complex biological bottlenecks of drug development, particularly in clinical trials, which remain slow and costly.

Non-specialist 'tourist investors,' often from the tech sector, are re-entering biotech, attracted by hype around AI and longevity. Their influence is leading to inflated valuations and connecting biotech stock performance to the whims of the tech market. This influx creates risk, as a downturn in tech could disproportionately harm biotech companies funded by this crossover capital.

The capital financing AI—from venture and credit to public markets—is so deeply interwoven that the system is fragile. Experts warn this creates systemic risk where a single negative event, like a major struggling AI IPO, could rapidly shift sentiment from the current "peak buoyancy" and trigger a broad market correction.

The systemic risk from a major AI company failing isn't the loss of its technology. It's the potential for its debt default to cascade through an opaque network of private credit and other lenders, triggering a financial crisis.

Unlike the 2008 financial crisis, which was a debt-fueled credit unwind, the current AI boom is largely funded by equity and corporate cash. Therefore, a potential correction will likely be an equity unwind, where the stock prices of major tech companies fall, impacting portfolios directly rather than triggering a systemic credit collapse.

Despite a stable flow of absolute dollars into biotech venture, the sector's relative share of all VC funding has shrunk from ~14% to ~7%. This is due to the denominator effect of massive capital flooding into AI-focused tech companies.

The massive influx of venture capital into AI has created a scarcity of funding for non-AI companies. This concentration of capital means that even strong startups in other sectors will find fundraising more challenging as VCs chase the outsized returns promised by the AI boom.

The rush to fund AI initiatives is diverting investment dollars away from other business-as-usual activities and industries. This concentrates systemic risk; if AI returns fall short of expectations, other economic engines will have been neglected and underfunded.